A latest tutorial case research, revealed on April 22, examined utilizing Amgen Inc’s AMGN Blincyto, a bispecific CD3xCD19 T-cell engager, to deal with a affected person with extreme systemic sclerosis.
The findings have implications for Cullinan Therapeutics Inc’s CGEM CLN-978, an analogous CD19xCD3 bispecific T-cell engager.
Most not too long ago, Cullinan Therapeutics, previously Cullinan Oncology, introduced its plans to increase into autoimmune ailments and intends to pursue the event of CLN-978 in autoimmune ailments, with systemic lupus erythematosus (SLE) as a primary indication.
William Blair notes that the case report demonstrates that Blincyto successfully handled a affected person with extreme systemic sclerosis, resulting in speedy B-cell depletion and symptom enchancment with out rising an infection threat or affecting antibody ranges.
This suggests the potential for utilizing B-cell-depleting remedy in autoimmune ailments like systemic lupus erythematosus (SLE), providing simpler administration than CAR-T remedy.
CLN-978’s improvement will initially goal SLE, with Section 1 submission deliberate for the third quarter.
William Blair charges Cullinan shares Outperform primarily based on the numerous potential of CLN-619 for endometrial and cervical most cancers, zipalertinib for exon 20 mutant lung most cancers, CLN-049 for leukemia, and CLN-978 for autoimmune ailments.
They consider the honest worth of every share is $33.
Up to date information for CLN-619, anticipated within the second quarter of 2024, will probably be a key catalyst for the corporate, together with updates for CLN-978 in lupus and different autoimmune indications.
The event of Cullinan’s different early-stage oncology property would supply further upside.
Earlier Wednesday, Cullinan Therapeutics introduced that medical information from its Section 1 trial of CLN-619 in sufferers with superior strong tumors will be offered on the 2024 American Society of Medical Oncology.
The info will embody the primary outcomes from the dose escalation cohort of CLN-619 together with checkpoint inhibitor pembrolizumab and up to date outcomes from the monotherapy dose-escalation cohort in sufferers with superior strong tumors.
Value Motion: CGEM shares are up 15.10% at $19.18 at the final examine Wednesday.
Photograph through PublicDomainPictures from Pixabay
